AR112284A1 - Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico - Google Patents

Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico

Info

Publication number
AR112284A1
AR112284A1 ARP180102058A AR112284A1 AR 112284 A1 AR112284 A1 AR 112284A1 AR P180102058 A ARP180102058 A AR P180102058A AR 112284 A1 AR112284 A1 AR 112284A1
Authority
AR
Argentina
Prior art keywords
acid
annulene
fluoropropyl
pyrrolidin
benzo
Prior art date
Application number
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR112284A1 publication Critical patent/AR112284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente memoria una combinación de palbociclib y del ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxílico o una de sus sales farmacéuticamente aceptables, una composición farmacéutica que contiene dicha combinación, y sus usos terapéuticos, en particular para el tratamiento del cáncer, incluyendo el cáncer de mama. Reivindicación 5: Una composición farmacéutica que comprende ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxílico, o una de sus sales farmacéuticamente aceptables, y palbociclib, y al menos un excipiente farmacéuticamente aceptable. Reivindicación 9: Compuesto ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxílico o una de sus sales farmacéuticamente aceptables para usar en el tratamiento de cáncer por coadministración con palbociclib.
ARP180102058 2017-07-24 2018-07-24 Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico AR112284A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762536121P 2017-07-24 2017-07-24
EP17305998.1A EP3434272A1 (en) 2017-07-25 2017-07-25 Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Publications (1)

Publication Number Publication Date
AR112284A1 true AR112284A1 (es) 2019-10-09

Family

ID=59569252

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102058 AR112284A1 (es) 2017-07-24 2018-07-24 Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico

Country Status (29)

Country Link
US (2) US11260057B2 (es)
EP (2) EP3434272A1 (es)
JP (1) JP6741897B1 (es)
KR (1) KR20200031622A (es)
CN (1) CN111107851B (es)
AR (1) AR112284A1 (es)
AU (1) AU2018308871A1 (es)
BR (1) BR112020001398A2 (es)
CA (1) CA3070754A1 (es)
CO (1) CO2020000240A2 (es)
DK (1) DK3658147T3 (es)
ES (1) ES2906279T3 (es)
HR (1) HRP20212030T1 (es)
HU (1) HUE057271T2 (es)
IL (1) IL272166B2 (es)
LT (1) LT3658147T (es)
MA (1) MA49673B1 (es)
MY (1) MY195271A (es)
PH (1) PH12020500091A1 (es)
PL (1) PL3658147T3 (es)
PT (1) PT3658147T (es)
RS (1) RS62837B1 (es)
RU (1) RU2764116C2 (es)
SG (1) SG11202000367RA (es)
SI (1) SI3658147T1 (es)
TW (1) TWI768087B (es)
UY (1) UY37818A (es)
WO (1) WO2019020559A1 (es)
ZA (1) ZA202000145B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2021002666A (es) * 2018-09-07 2021-07-16 Sanofi Sa Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.
JP2022531898A (ja) * 2019-05-09 2022-07-12 サノフイ 転移性または進行性***がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸
CA3160897A1 (en) * 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combinations containing abamciclib, and 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL]OXYPHENYL]-8,9-DIHYDRO-7H-BENZO [7]ANNULENE-2-CARBOXYLIC ACID
TW202302084A (zh) * 2021-03-02 2023-01-16 法商賽諾菲公司 以安森司坦和帕博西尼治療乳癌
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
KR20230130261A (ko) 2022-03-03 2023-09-12 인하대학교 산학협력단 암의 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1229036B1 (en) 2001-01-24 2005-01-12 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
WO2003016270A2 (en) 2001-08-11 2003-02-27 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
DK1501819T3 (da) 2002-04-24 2011-01-10 Merck Sharp & Dohme Østrogenreceptormodulatorer
JP4500689B2 (ja) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
CA2571587C (en) 2004-06-25 2013-02-12 Janssen Pharmaceutica, N.V. Quaternary salt ccr2 antagonists
JP5354775B2 (ja) 2005-06-14 2013-11-27 ベイラー ユニバーシティ チューブリン結合活性を有するコンブレタスタチンアナログ
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2861939A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性***受体调节剂的乙烯衍生物
HUE057061T2 (hu) * 2013-08-14 2022-04-28 Novartis Ag Kombinációs terápia rák kezelésére
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2016097072A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3233828B1 (en) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
IL255148B2 (en) * 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
CN106924210A (zh) * 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
JP6425852B1 (ja) 2016-02-15 2018-11-21 サノフイＳａｎｏｆｉ エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
WO2018091153A1 (en) 2016-11-17 2018-05-24 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2021002666A (es) 2018-09-07 2021-07-16 Sanofi Sa Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.
CA3119742A1 (en) * 2018-11-16 2020-05-22 Arqule, Inc. Pharmaceutical combination for treatment of cancer

Also Published As

Publication number Publication date
KR20200031622A (ko) 2020-03-24
BR112020001398A2 (pt) 2020-07-28
US20200171033A1 (en) 2020-06-04
EP3658147B1 (en) 2021-11-10
SI3658147T1 (sl) 2022-02-28
ZA202000145B (en) 2021-07-28
US11260057B2 (en) 2022-03-01
PH12020500091A1 (en) 2020-09-14
IL272166B2 (en) 2023-04-01
CN111107851A (zh) 2020-05-05
RU2020107416A (ru) 2021-08-25
LT3658147T (lt) 2022-01-10
MY195271A (en) 2023-01-11
WO2019020559A1 (en) 2019-01-31
JP6741897B1 (ja) 2020-08-19
DK3658147T3 (da) 2022-01-31
HUE057271T2 (hu) 2022-04-28
IL272166B (en) 2022-12-01
JP2020526572A (ja) 2020-08-31
ES2906279T3 (es) 2022-04-18
EP3658147A1 (en) 2020-06-03
CN111107851B (zh) 2023-05-12
SG11202000367RA (en) 2020-02-27
IL272166A (en) 2020-03-31
EP3434272A1 (en) 2019-01-30
CA3070754A1 (en) 2019-01-31
HRP20212030T1 (hr) 2022-04-01
PT3658147T (pt) 2022-02-02
AU2018308871A1 (en) 2020-02-06
PL3658147T3 (pl) 2022-03-07
US20220362248A1 (en) 2022-11-17
MA49673A (fr) 2021-03-24
CO2020000240A2 (es) 2020-04-24
TWI768087B (zh) 2022-06-21
UY37818A (es) 2020-08-31
RU2764116C2 (ru) 2022-01-13
MA49673B1 (fr) 2022-02-28
RS62837B1 (sr) 2022-02-28
RU2020107416A3 (es) 2021-08-25
TW201919612A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CO2018002060A2 (es) Compuestos farmacéuticos
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CL2019000056A1 (es) Sales y formas cristalinas del ácido 2-(3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-(s)-1(isopropilsufonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético; proceso de preparación de una de las sales; composición farmacéutica que comprende; útiles para tratar cáncer. (solicitud divisional 201503589)
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
CR20140086A (es) Tratamientos de combinación para hepatitis c
AR103680A1 (es) Inhibidores selectivos de bace1
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NI201800071A (es) Compuestos de isoindol
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase